Compare Cytokinetics Inc (CYTK) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs KeyCorp — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while KeyCorp trades at $20.14 (market cap $21.16B). The key difference: KeyCorp is far larger — about 2.5× Cytokinetics Inc's market cap, and KeyCorp pays a 4.14% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and KeyCorp for 66 Days on average.
| CYTK | KEY | |
|---|---|---|
Market Cap | $8.50B | $21.16B |
Volume | 2,395,556 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $87.26 | $23.99 |
52-Week Low | $54.76 | $16.78 |
Typical Hold Time | 19 Days | 66 Days |
Enterprise Value | $8.60B | $34.34B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
KeyCorp (KEY) trades at $19.83, down 1.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank has beaten EPS estimates for three consecutive quarters, with a Q3 2026 estimate of $0.4615. Revenue rebounded to $7.29B in 2025, and the net income margin improved to 26.72%. Recent corporate actions include a $0.21 dividend and key executive appointments in wealth and retail banking.
The outlook is cautiously optimistic, supported by strong analyst consensus (60.79% buy rating) and a $25.00 price target implying 26% upside. Investment opportunities include earnings momentum and shareholder returns via dividends and buybacks. Risks involve interest rate sensitivity, competitive pressures on margins, and macroeconomic uncertainty affecting loan growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
